Citigroup
NPCE icon

Citigroup’s Neuropace NPCE Stock Holding History

Citigroup’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8K Buy
1,047
+471
+82% +$7.07K ﹤0.01% 4927
2025
Q4 		$8.89K Sell
576
-458
-44% -$6.13K ﹤0.01% 5096
2025
Q3 		$10.7K Sell
1,034
-7,560
-88% -$71.3K ﹤0.01% 5007
2025
Q2 		$95.7K Sell
8,594
-1,500
-15% -$18.8K ﹤0.01% 4423
2025
Q1 		$124K Sell
10,094
-1,013
-9% -$12.7K ﹤0.01% 4480
2024
Q4 		$124K Buy
11,107
+1,263
+13% +$11K ﹤0.01% 4722
2024
Q3 		$68.6K Buy
9,844
+6,875
+232% +$50.3K ﹤0.01% 4915
2024
Q2 		$22.4K Sell
2,969
-72,719
-96% -$734K ﹤0.01% 4973
2024
Q1 		$999K Buy
75,688
+40,667
+116% +$580K ﹤0.01% 3026
2023
Q4 		$361K Buy
35,021
+32,037
+1,074% +$255K ﹤0.01% 3618
2023
Q3 		$29K Buy
+2,984
New +$17.5K ﹤0.01% 4292
2022
Q3 		– Sell
-62
Closed – – 6172
2022
Q2 		$0 Sell
62
-194
-76% -$1.28K ﹤0.01% 6518
2022
Q1 		$2K Sell
256
-1,583
-86% -$13.7K ﹤0.01% 6080
2021
Q4 		$19K Buy
1,839
+1,021
+125% +$13.3K ﹤0.01% 5399
2021
Q3 		$13K Buy
818
+487
+147% +$10.2K ﹤0.01% 5404
2021
Q2 		$8K Buy
+331
New +$7.68K ﹤0.01% 5741

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citigroup's NPCE Position: Q1 2026 in Review

Citigroup increased its Neuropace (NPCE) stake by 82% in Q1 2026, buying an estimated $7.07K and bringing the position to 1,047 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4927.

Citigroup first reported a position in NPCE in Q2 2021 and has held it in 16 quarters since. The position peaked at $999K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Citigroup held 1,047 shares of Neuropace worth $13.8K as of Q1 2026.
  • Citigroup bought 471 Neuropace shares in Q1 2026, an estimated $7.07K.
  • Neuropace made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4927 holding.
  • Citigroup first reported a position in Neuropace in Q2 2021 and has held it in 16 quarters since.
  • Citigroup's Neuropace position peaked at $999K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.